Chargement de la fiche…
rhumatologie
Dr Camelia Frantz
Hospitalier
Saint-Mandé (94160)
Biothérapies non-anti-TNF · Génétique · Arthrite juvénile
0Publications
0Citations de la publi la +
Côté patient
Avant votre rendez-vous avec le Dr Camelia Frantz
Choisissez votre pathologie pour une explication en langage simple.
Parcourir toutes les pathologies →Des applications évaluées par MonRhumato, sélectionnées pour les patients.
MapathoPlateforme communautaire maladies chroniques + annuaire pair-validé
GustaveAgent IA souverain pour information patient sourcée
Remedee LabsBracelet stimulateur d'endorphines pour douleur chroniquePourquoi consulter Dr Camelia Frantz
- Praticien-chercheur
- Délais de RDV courts dans la région
Tout est calculé à partir des sources publiques (RPPS, PubMed, OpenAlex, OpenStreetMap…) — aucun classement éditorial.
Dernières publications
Publications les plus citées
91 citationsImpaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey2016 · Seminars in arthritis and rheumatismPubMed ↗81 citationsPan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis2016 · Annals of the rheumatic diseasesPubMed ↗79 citationsRegulatory T Cells in Systemic Sclerosis2018 · Frontiers in immunologyPubMed ↗
Diplômes & qualifications
DES
DES Rhumatologie · Rhumatologie (SM) — Diplôme d'Études Spécialisées
CES
DE Docteur en médecine · DIU Etudes approfondies polyarthrites-maladies — Capacité / Certificat d'Études Spéciales
DU / DIU
DIU Études approfondies polyarthrites & maladies auto-immunes
Le DIU rhumato généraliste de référence : polyarthrite rhumatoïde, spondyloarthrite, lupus, Sjögren, vascularites. Coordonné par la SFR.
Plusieurs universités, coordination Société Française de Rhumatologie (SFR)
Lieu d'exercice
Domaines d'expertise
Biothérapies non-anti-TNFGénétiqueArthrite juvénileBiomarqueurs / Auto-AccsDMARDs
Transversal
102026La Revue de medecine interne
PubMed ↗[Pasteurella multocida septic arthritis in a native joint: Management dilemmas in a penicillin-allergic patient]
2022The Journal of rheumatology
PubMed ↗Evaluation of Patients With Rheumatoid Arthritis in Teleconsultation During the First Wave of the COVID-19 Pandemic
2022Arthritis & rheumatology (Hoboken, N.J.)
PubMed ↗Driving Role of Interleukin-2-Related Regulatory CD4+ T Cell Deficiency in the Development of Lung Fibrosis and Vascular Remodeling in a Mouse Model of Systemic Sclerosis
2022Revue du rhumatisme (Ed. francaise : 1993)
PubMed ↗Évaluation systématique de la réponse humorale contre le SARS-CoV-2 dans une cohorte française de 283 patients atteints d’un rhumatisme inflammatoire chronique
2022Joint bone spine
PubMed ↗Systematic assessment of the humoral response against SARS-CoV-2 in a French cohort of 283 patients with rheumatic diseases
2020Autoimmunity reviews
PubMed ↗Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database
2019Clinical and experimental rheumatology
PubMed ↗Acute anterior uveitis in spondyloarthritis: a monocentric study of 301 patients
2018Frontiers in immunology
PubMed ↗Regulatory T Cells in Systemic Sclerosis
2017Joint bone spine
PubMed ↗Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma
2016Annals of the rheumatic diseases
PubMed ↗Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis
Biothérapies non-anti-TNF
22021Revue du rhumatisme (Ed. francaise : 1993)
PubMed ↗Passage du tocilizumab ou de l’abatacept de la forme intraveineuse vers la voie sous-cutanée pendant la pandémie de COVID-19 : expérience française
2016Annals of the rheumatic diseases
PubMed ↗Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis
Génétique
2Arthrite juvénile
12023Joint bone spine
PubMed ↗Risk stratification using anti-citrullinated peptide antibodies (ACPA) in polyarticular subtypes of juvenile idiopathic arthritis in adulthood
Biomarqueurs / Auto-Ac
12018Disease markers
PubMed ↗Soluble CD163 as a Potential Biomarker in Systemic Sclerosis
csDMARDs
12022Clinical and experimental rheumatology
PubMed ↗Risk of liver fibrosis induced by methotrexate and other rheumatoid arthritis medications according to the Fibrosis-4 Index
Qualité de vie / PROMs
12016Seminars in arthritis and rheumatism
PubMed ↗Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey
Sclérodermie
12024Journal of scleroderma and related disorders
PubMed ↗Deficiency and altered phenotype of mucosal-associated invariant T cells in systemic sclerosis
Publications HAL
82023Article
Risk stratification using anti-citrullinated peptide antibodies (ACPA) in polyarticular subtypes of juvenile idiopathic arthritis in adulthood
Joint Bone Spine
2022Article
Driving Role of Interleukin‐2–Related Regulatory CD4 + T Cell Deficiency in the Development of Lung Fibrosis and Vascular Remodeling in a Mouse Model of Systemic Sclerosis
Arthritis & rheumatology
2022Article
IL ‐2‐related regulatory CD4 T‐cell deficiency leads to the development of lung fibrosis and vascular remodeling
Arthritis & rheumatology
2020Article
Outcomes of limited cutaneous systemic sclerosis patients: results on more than 12,000 patients from the eustar database
Autoimmunity Reviews
2018Article
Regulatory T Cells in Systemic Sclerosis
Frontiers in Immunology
2018Article
Soluble CD163 as a Potential Biomarker in Systemic Sclerosis
Disease Markers
2016Article
Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis
Annals of the Rheumatic Diseases
2015Article
Combined effect of genetic background and gender in a mouse model of bleomycin-induced skin fibrosis
Arthritis Research and Therapy
Rhumatologues à proximité
Données issues de l'Annuaire Santé (ANS) — Licence Ouverte 2.0. Enrichissements à partir de sources publiques. Vous êtes le praticien référencé ? Faites corriger ou retirer votre fiche : demande de rectification ou de retrait.